Spinal Muscular Atrophy (SMA) is a rare genetic disorder that affects the motor neurons in the spinal cord, leading to progressive muscle weakness and wasting. It is the leading genetic cause of death in infants and young children. Healthcare services for SMA include diagnosis, treatment, and management of the condition. Diagnosis is typically done through genetic testing, and treatment may include physical therapy, occupational therapy, and medications. Management of SMA includes monitoring of the patient's condition, providing support and education to the patient and their family, and providing access to resources and services.
Companies in the SMA market include Biogen, Novartis, AveXis, and PTC Therapeutics. Show Less Read more
